Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Thomas K. Karikari, Nicholas J. Ashton, Gunnar Brinkmalm, et al.
Nature Reviews Neurology (2022) Vol. 18, Iss. 7, pp. 400-418
Closed Access | Times Cited: 211

Showing 1-25 of 211 citing articles:

Hallmarks of neurodegenerative diseases
David M. Wilson, Mark Cookson, Ludo Van Den Bosch, et al.
Cell (2023) Vol. 186, Iss. 4, pp. 693-714
Open Access | Times Cited: 801
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
Nicholas J. Ashton, Shorena Janelidze, Niklas Mattsson, et al.
Nature Medicine (2022) Vol. 28, Iss. 12, pp. 2555-2562
Open Access | Times Cited: 247
Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
Nicholas J. Ashton, Wagner S. Brum, Guglielmo Di Molfetta, et al.
JAMA Neurology (2024) Vol. 81, Iss. 3, pp. 255-255
Open Access | Times Cited: 246
Blood biomarkers for Alzheimer’s disease in clinical practice and trials
Oskar Hansson, Kaj Blennow, Henrik Zetterberg, et al.
Nature Aging (2023) Vol. 3, Iss. 5, pp. 506-519
Open Access | Times Cited: 220
Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration
Fernándo González‐Ortiz, Michael Turton, Przemysław R. Kac, et al.
Brain (2022) Vol. 146, Iss. 3, pp. 1152-1165
Open Access | Times Cited: 140
Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape
Harald Hampel, Yan Hu, Jeffrey L. Cummings, et al.
Neuron (2023) Vol. 111, Iss. 18, pp. 2781-2799
Open Access | Times Cited: 118
A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
Wagner S. Brum, Nicholas Cullen, Shorena Janelidze, et al.
Nature Aging (2023) Vol. 3, Iss. 9, pp. 1079-1090
Open Access | Times Cited: 112
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Fernándo González‐Ortiz, Przemysław R. Kac, Wagner S. Brum, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 111
Plasma proteomic profiles predict future dementia in healthy adults
Yu Guo, Jia You, Yi Zhang, et al.
Nature Aging (2024) Vol. 4, Iss. 2, pp. 247-260
Closed Access | Times Cited: 107
The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review
Abby L. Brand, Paige E. Lawler, James G. Bollinger, et al.
Alzheimer s Research & Therapy (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 92
Equivalence of plasma p‐tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease
Joseph Therriault, Stijn Servaes, Cécile Tissot, et al.
Alzheimer s & Dementia (2023) Vol. 19, Iss. 11, pp. 4967-4977
Open Access | Times Cited: 82
Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease
Suzanne E. Schindler, Douglas Galasko, Ana C. Pereira, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 7, pp. 426-439
Open Access | Times Cited: 70
Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies
Laia Montoliu‐Gaya, Andréa Lessa Benedet, Cécile Tissot, et al.
Nature Aging (2023) Vol. 3, Iss. 6, pp. 661-669
Open Access | Times Cited: 60
Biomarker-based staging of Alzheimer disease: rationale and clinical applications
Joseph Therriault, Suzanne E. Schindler, Gemma Salvadó, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 4, pp. 232-244
Closed Access | Times Cited: 55
The dynamics of plasma biomarkers across the Alzheimer’s continuum
Yu Guo, Xue‐Ning Shen, Hui-Fu Wang, et al.
Alzheimer s Research & Therapy (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 54
Cardiovascular Disease and Alzheimer's Disease: The Heart–Brain Axis
Anum Saeed, Oscar L. López, Ann D. Cohen, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 21
Open Access | Times Cited: 54
A novel ultrasensitive assay for plasma p‐tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease
Fernándo González‐Ortiz, Pâmela C.L. Ferreira, Armand González‐Escalante, et al.
Alzheimer s & Dementia (2023) Vol. 20, Iss. 2, pp. 1239-1249
Open Access | Times Cited: 44
Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort
Augusto J. Mendes, Federica Ribaldi, Aurélien Lathuilière, et al.
Journal of Neurology (2024) Vol. 271, Iss. 4, pp. 2053-2066
Open Access | Times Cited: 29
Alzheimer’s Disease Detection Using Deep Learning on Neuroimaging: A Systematic Review
Mohammed Alsubaie, Suhuai Luo, Kamran Shaukat
Machine Learning and Knowledge Extraction (2024) Vol. 6, Iss. 1, pp. 464-505
Open Access | Times Cited: 27
Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer’s disease neuropathology
Przemysław R. Kac, Fernándo González‐Ortiz, Andreja Emeršič, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 22
Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease
Fernándo González‐Ortiz, Bjørn‐Eivind Kirsebom, José Contador, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 22
Clinical evaluation of a novel plasma pTau217 electrochemiluminescence immunoassay in Alzheimer’s disease
Pia Kivisäkk, Hadia Fatima, Danielle S. Cahoon, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 21
Biomarkers of Alzheimer's disease and neurodegeneration in dried blood spots—A new collection method for remote settings
Hanna Huber, Kaj Blennow, Henrik Zetterberg, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 4, pp. 2340-2352
Open Access | Times Cited: 21
Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting
Xuemei Zeng, Yijun Chen, Anuradha Sehrawat, et al.
Molecular Neurodegeneration (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 17
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology
Joseph Therriault, Marcel S. Woo, Gemma Salvadó, et al.
Molecular Neurodegeneration (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top